AstraZeneca will fall to Pfizer once the price is right, even if British politicians are jumping up and down

Only the shareholders have the ability to refuse and they’re mandated to seek the best return

When Kraft bid for Cadbury, I recall having a conversation with someone senior at the British chocolate maker as to what would be an acceptable offer.

“I reckon you’ve got 850p in your head,” I said. The Cadbury man spluttered, and tried to say there were other considerations as well. He stressed that he and his colleagues were determined to stand and fight, to do everything they could to halt the would-be US acquirer. He was not going to be drawn on a discussion about the numbers. Note, though, that he did not deny it either.

This was not rocket science on my part. All I’d done was do a ring round of a few City analysts and ask them for the figure at which they thought Cadbury shareholders would run up the white flag – or rather, the investor institutions would walk off with a fat profit, leaving the historic British firm in the hands of the US predator.

Forget the huffing and puffing, the raging about a foreigner coming in. That sort of stuff is for the politicians, unions, local communities where jobs may be threatened. They are right to be concerned – such bids are not necessarily a good thing for the UK. But from Day One, the City will have had a target number in mind. Pay that and Cadbury is yours; fall short and you won’t get it.

So it is with Pfizer and AstraZeneca. What’s the price which the AstraZeneca board is holding out for, and if it’s achieved, will see it throw in the towel, heads held high? I reckon £59-£60 a share. Already, Pfizer has tabled a bid of £50. Up it a bit more, and again, until you reach £59, and the British firm will fall. To be fair, some shareholders have indicated that they would prefer to stick with AstraZeneca, but this is what most of the City institutions are likely to be looking for.

Let’s be clear: they’re one of two sets of people who matter in this proposed takeover. The other is the Eurocrats in Brussels. This is a big enough deal to come within EU mergers regulations. Only the European Commission can block it, and it’s not clear whether it would have reason to, since the criterion by which it assesses such mergers is solely the effect on competition, not on such things as jobs or the science base.

I’ve left out another grouping; one that we British might suppose carries weight and has enormous power in these affairs. That, of course, is our own political masters at Westminster.

The truth is there is absolutely nothing they can do to prevent Pfizer coming in and grabbing AstraZeneca. At the moment there is a lot of posturing going on, with Ed Miliband, in particular, jumping up and down, accusing David Cameron of acting as “cheerleader” for the American company’s £63bn move.

But Ed, be honest now. If you were Prime Minister today, what could you do to shoo Pfizer away? The answer, as you and I well know, is precisely nothing. It’s possible that a clause could be added to the Enterprise and Regulatory Reform Act 2013, adding research and development to the types of mergers that can prompt government intervention, namely those affecting our defence interests, media, and financial stability. However, even if that were to be done, ministers would still be powerless to act since the case falls under EU jurisdiction, and would not come to them for a decision.

In theory, the UK could press to reform the EU regulations, so that mergers of this kind would be judged under different criteria. But that would take an age, and would definitely fall outside the timeframe of the mooted Pfizer-AstraZeneca marriage. If Ed Miliband is saying that, as PM, the UK would seek such a change, then good luck to him in achieving EU-wide consensus on that one.

Vince Cable knows this, too. The Business Secretary appears to be opposed to the deal, but is markedly unspecific on the point of how he, as the Cabinet member in charge of such things, could actually do anything about it. Mr Cable wants to be seen to be more caring than the Tories – and to be fair, he probably is more concerned about the impact on jobs and our R&D expertise – and he’s anxious that Labour does not present itself as the only party that backs British business. But while he says he is concerned about the bid on “public interest grounds”, there is precious little he can do to put his words into action.

Ironically, in his four years as Business Secretary, if he cared so much about this, Mr Cable could have sought to change the rules to make it more difficult for foreigners to buy up our assets. His department passed new legislation on the competition rules just last year, while the European Commission has been consulting the UK (and other countries) on reforming its merger regulations. But what has he done about it? Zero. Mr Cable even made a point of saying Lord Heseltine was wrong in his review into UK economic growth to say there should be a failsafe mechanism for UK government intervention in takeovers of key UK assets by overseas companies. It’s a bit rich of Mr Cable, now, to turn round and complain about Pfizer.

Mr Cameron is aware of all this as well. Asking the Cabinet Secretary Sir Jeremy Heywood and Treasury mandarin Sir John Kingman to assess the Pfizer plan is pure window-dressing, nothing more, nothing less. It’s the classic ruse of a PM wanting to be seen to be doing something, a ploy designed to secure some decent PR, when he knows that in reality Sir Jeremy and Sir John’s findings have no real significance whatsoever.

All the intrepid duo can do is dream up some assurances that Pfizer must sign up to in order to obtain government backing. These though, will have no legal authority.

Pfizer has thought of some commitments of its own, saying in a letter to Mr Cameron that the number of jobs in the UK will be held constant for five years, a new R&D park will still be built in Cambridge, and 20 per cent of Pfizer’s group science will be domiciled in Britain.

But the jobs guarantee is only provided unless “circumstances significantly change”; the Cambridge site was already going to be developed; and 20 per cent of the combined group’s staff would be in the UK anyway. In other words, the letter is full of platitudes and get-outs. Pfizer can tear it up four years hence and the government of the day, even one with Mr Miliband at the helm, will only be able to watch, powerless.

Pfizer’s bosses are only human. The best hope of stopping them is to scream and shout – they have no desire to be unpopular, they will crave acceptance. There are real issues at stake here and if the anti-Pfizer movement is vocal enough it may well resonate in the US giant’s boardroom.

Likewise, at least two Parliamentary select committees are gearing up to interview the Pfizer and AstraZeneca management. Again, that is not something the Pfizer folk will relish. We should, though, be under no illusion: it is only noise. The MPs can recommend as much as they like but select committees have no decision-making powers even here in the UK, still less in Brussels, so they’re in no position to head off the Pfizer purchase.

We’ve been here before, with Kraft. Its chief, Irene Rosenfeld, did not even deign to appear before MPs, such was their supposed hold over her. Public promises as to future conduct were made by her company and then it ignored them. Why? Because it can.

If Pfizer is made of similarly stern stuff, it too can behave the same way. In the end, despite a massive amount of energy, and money, expended on anti-Kraft campaigns, MPs and others taking to the ramparts, sections of the media going wild with fury, the British company fell. What was the price it went for? 850p a share. It was always going to.

AstraZeneca, sadly, is no different. Only the shareholders have the ability to refuse and they’re mandated to seek the best return on their investments for their clients, the funds in which we hold our pensions. Their decisions may or may not be good for the UK, but unless the politicians want to add policy on large mergers to the list of items to  be renegotiated with Brussels, then it is  what it is.

PROMOTED VIDEO
Arts and Entertainment
tv
News
Katie Hopkins appearing on 'This Morning' after she purposefully put on 4 stone.
peopleKatie Hopkins breaks down in tears over weight gain challenge
Life and Style
fashionModel of the moment shoots for first time with catwalk veteran
Life and Style
fashionAngelina Jolie's wedding dressed revealed
News
i100
Sport
Alexis Sanchez, Radamel Falcao, Diego Costa and Mario Balotelli
footballRadamel Falcao and Diego Costa head record £835m influx
News
i100
News
ebooksAn unforgettable anthology of contemporary reportage
Arts and Entertainment
Madame Vastra and Jenny Flint kiss in Doctor Who episode 'Deep Breath'
tv
Arts and Entertainment
Olivia Colman topped the list of the 30 most influential females in broadcasting
tv
Life and Style
techIf those brochure kitchens look a little too perfect to be true, well, that’s probably because they are
Arts and Entertainment
Danish director Lars von Trier
tvEnglish-language series with 'huge' international cast set for 2016
Life and Style
tech
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Executive Assistant/Events Coordinator - Old Street, London

£35000 - £38000 per annum + benefits: Ashdown Group: Executive Assistant/Event...

HR Generalist (standalone) - Tunbridge Wells - £32,000

£30000 - £32000 per annum: Ashdown Group: HR Generalist (standalone) - Tunbrid...

Derivatives Risk Commodities Business Analyst /Market Risk

£600 - £800 per day: Harrington Starr: Derivatives Risk Commodities Business A...

Power & Gas Business Analyst / Subject Matter Expert - Contract

£600 - £800 per day: Harrington Starr: Power & Gas Business Analyst/Subject Ma...

Day In a Page

'I’ll tell you what I would not serve - lamb and potatoes': US ambassador hits out at stodgy British food served at diplomatic dinners

'I’ll tell you what I would not serve - lamb and potatoes'

US ambassador hits out at stodgy British food
Radio Times female powerlist: A 'revolution' in TV gender roles

A 'revolution' in TV gender roles

Inside the Radio Times female powerlist
Endgame: James Frey's literary treasure hunt

James Frey's literary treasure hunt

Riddling trilogy could net you $3m
Fitbit: Because the tingle feels so good

Fitbit: Because the tingle feels so good

What David Sedaris learnt about the world from his fitness tracker
Saudis risk new Muslim division with proposal to move Mohamed’s tomb

Saudis risk new Muslim division with proposal to move Mohamed’s tomb

Second-holiest site in Islam attracts millions of pilgrims each year
Alexander Fury: The designer names to look for at fashion week this season

The big names to look for this fashion week

This week, designers begin to show their spring 2015 collections in New York
Will Self: 'I like Orwell's writing as much as the next talented mediocrity'

'I like Orwell's writing as much as the next talented mediocrity'

Will Self takes aim at Orwell's rules for writing plain English
Meet Afghanistan's middle-class paint-ballers

Meet Afghanistan's middle-class paint-ballers

Toy guns proving a popular diversion in a country flooded with the real thing
Al Pacino wows Venice

Al Pacino wows Venice

Ham among the brilliance as actor premieres two films at festival
Neil Lawson Baker interview: ‘I’ve gained so much from art. It’s only right to give something back’.

Neil Lawson Baker interview

‘I’ve gained so much from art. It’s only right to give something back’.
The other Mugabe who is lining up for the Zimbabwean presidency

The other Mugabe who is lining up for the Zimbabwean presidency

Wife of President Robert Mugabe appears to have her sights set on succeeding her husband
The model of a gadget launch: Cultivate an atmosphere of mystery and excitement to sell stuff people didn't realise they needed

The model for a gadget launch

Cultivate an atmosphere of mystery and excitement to sell stuff people didn't realise they needed
Alice Roberts: She's done pretty well, for a boffin without a beard

She's done pretty well, for a boffin without a beard

Alice Roberts talks about her new book on evolution - and why her early TV work drew flak from (mostly male) colleagues
Get well soon, Joan Rivers - an inspiration, whether she likes it or not

Get well soon, Joan Rivers

She is awful. But she's also wonderful, not in spite of but because of the fact she's forever saying appalling things, argues Ellen E Jones
Doctor Who Into the Dalek review: A classic sci-fi adventure with all the spectacle of a blockbuster

A fresh take on an old foe

Doctor Who Into the Dalek more than compensated for last week's nonsensical offering